Diag2Tec – Preclinical CRO in Multiple Myeloma, Lymphoma, Leukemia
  • Home
  • Our Expertise
    • Multiple Myeloma
    • Hematological Cancer Cell Lines & Primary Cells
    • In Vitro Model of Human Plasma Cell Differentiation
    • Flow Cytometry
    • NGS – Biomarkers – New Therapeutic Targets Identification
  • Preclinical Services
    • In vitro Drug Testing
    • Immunotherapies : Assays and Analyses
    • Prognosis and Predictive Biomarkers
  • R&D
    • Our ChimioFX Platform
  • About us
    • Team & History
    • Prospects and Partners
    • ISO 9001: 2015 Certification
  • Press & News
    • List of Publications and Patents
    • Our News
  • Contact
    • Contact us
    • Opportunities
logo

Montpellier’s BIC

Home → News → Montpellier’s BIC

http://www.montpellier3m.fr/actualite/montpellier-mediterranee-metropole-chef-de-file-de-la-lutte-contre-le-cancer

By admin on February 2, 2018   /   News  
Our abstract has been selected for a poster presentation in the Annual Congres of American Society of Hematology in 2017 (San Diego).
 Previous Post
2017 Annual Congress of American Society of Hematology
Next Post  
BioPharlAnalyses

Diag2Tec’s Headquarters

Diag2Tec
Immeuble le Stratège
1095 Rue Henri Becquerel
34000 Montpellier FRANCE

Diag2Tec’s Laboratories

CHU St Eloi, Dpt Hematology Biology
80 Av Augustin Fliche
34295 Montpellier FRANCE
Diag2Tec logo

  Contact us

Documentation

Services brochure
Publications and Patents
ISO 9001 Certification

Preclinical Services

In vitro Drug Testing
Immunotherapies : Assays and Analysis
Prognosis and Predictive Biomarkers
© Diag2Tec all rights reserved - Legal Notice
Back to Top